Paper Details

  1. Home
  2. Paper Details

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

Author: , ApperleyJane F, BacigalupoAndrea, BeksacMeral, BorkettKeith, BradstockKen, BuzynAgnes, ClarkPeter, GluckmanEliane, GorinNorbert C, GratwohlAlois, HasencleverDirk, NaglerArnon, RussellNigel, RuutuTapani, SchmitzNorbert, SzerJeff

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The study compares the use of allogeneic mobilized peripheral blood progenitor cells to bone marrow transplantation for restoring hematopoiesis after myeloablative therapy.
Paper Details　
Original Abstract of the Article :
Allogeneic mobilized peripheral blood progenitor cells instead of bone marrow are increasingly used to restore hematopoiesis after myeloablative therapy. Data supporting this important change of clinical practice are scarce. We therefore assigned patients with early leukemias to peripheral blood or ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12130483

データ提供：米国国立医学図書館（NLM）

Mobilized Peripheral Blood Cells: A New Oasis for Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for patients with hematological malignancies. While bone marrow has been the traditional source of stem cells, mobilized peripheral blood progenitor cells have emerged as an alternative option. This study compares the outcomes of HSCT using mobilized peripheral blood cells versus bone marrow cells in HLA-identical sibling donors for patients with standard-risk leukemia. The researchers meticulously evaluated the occurrence of graft versus host disease (GVHD), survival rates, and other important outcomes.

Navigating the Shifting Sands of HSCT

This study demonstrates that mobilized peripheral blood cells are an equivalent source of hematopoietic stem cells compared to bone marrow for patients with standard-risk leukemias. The researchers found that while mobilized peripheral blood cells resulted in a faster neutrophil and platelet recovery, they also led to a higher incidence of acute and chronic GVHD. However, the overall survival rates, relapse rates, and transplantation-related mortality did not significantly differ between the two stem cell sources. This research sheds light on the complex landscape of HSCT and the potential benefits and challenges associated with different stem cell sources.

A Journey Towards a More Accessible Oasis

This study provides valuable insights into the evolving landscape of HSCT. The findings suggest that mobilized peripheral blood cells can serve as a viable alternative to bone marrow for patients with standard-risk leukemias. However, the higher incidence of GVHD highlights the need for ongoing research to optimize the use of mobilized peripheral blood cells and to minimize the risk of complications. It's a reminder that even in the vast and unforgiving desert of hematological research, new discoveries can emerge, offering us a chance to find more effective and accessible treatment options for those in need.

Dr.Camel's Conclusion

This study provides valuable insights into the potential of mobilized peripheral blood cells as a source of hematopoietic stem cells for patients with standard-risk leukemias. While offering a faster recovery, the study also highlights the need for careful consideration of the increased risk of GVHD. As we continue to explore the vast and unforgiving desert of hematological research, this study serves as a valuable guide for navigating the complexities of HSCT and for developing more effective and accessible treatment options for patients.

Date :
  1. Date Completed 2002-09-06
  2. Date Revised 2021-02-06
Further Info :

Pubmed ID

12130483

DOI: Digital Object Identifier

S0006-4971(20)59371-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.